SCND Scientific Industries (SCND) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0000087802
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about SCND
Insiders, 180 days
+$17.1K net bought
1 buyer
Scientific Industries insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, SCIENTIFIC INDUSTRIES INC insiders bought a net $17.1K of stock across 45 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Jun 2, 2026.
- -9.9% median (-8.3% mean) 90-day return after 14 previous buys.
- The trade is 1.6% of the 945,641 shares held after it.
- No other insider bought within 30 days.
Insider activity: Chairman of the Board MOORE JOHN A bought about $10.5K of SCND on Aug 20, 2026.Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Jun 2, 2026.
- -9.9% median (-8.3% mean) 90-day return after 14 previous buys.
- The trade is 0.5% of the 950,641 shares held after it.
- No other insider bought within 30 days.
Insider activity: Chairman of the Board MOORE JOHN A bought about $3.8K of SCND on Aug 20, 2026.Context
- 15 earlier Form 4 trades (code P or S) here by this insider (15 buys), the last on Mar 23, 2026.
- -13.6% median (-9.8% mean) 90-day return after 13 previous buys.
- The trade is 0.4% of the 930,871 shares held after it.
- No other insider bought within 30 days.
Insider activity: Chairman of the Board MOORE JOHN A bought about $2.8K of SCND on Jun 2, 2026.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 buys), the last on Feb 19, 2026.
- -14.6% median (-10.4% mean) 90-day return after 12 previous buys.
- The trade is 1.0% of the 926,871 shares held after it.
- No other insider bought within 30 days.
Insider activity: Chairman MOORE JOHN A bought about $5.2K of SCND on Mar 23, 2026.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Dec 17, 2025.
- -15.6% median (-12.9% mean) 90-day return after 11 previous buys.
- The trade is 0.1% of the 917,871 shares held after it.
- No other insider bought within 30 days.
Insider activity: Chairman of the Board MOORE JOHN A bought about $650 of SCND on Feb 19, 2026.45 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$17.1K over 180 days
+$14.3K over 90 days
more than 68% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+5.4% year over year
below 63% of Medical Devices
Margin
-24.1% net margin
below 55% of Medical Devices
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
the lowest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SCND
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-0.9%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SCND: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in SCND
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SCND planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $17.1K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
SCND financials
Revenue growth
+5.4%
XBRL, annual
Net margin
-24.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Revenue, TTM SCND
| FY Dec 2025 | n/a |
| FY Dec 2024 | $10.7M |
| FY Dec 2023 | $11.1M |
| FY Jun 2022 | $11.4M |
| FY Jun 2021 | n/a |
| Jun 2026 | $1.5M |
| Mar 2026 | $1.2M |
| Dec 2025 | $1.6M |
| Sep 2025 | $1.4M |
| Jun 2025 | $2.3M |
| Mar 2025 | $2.4M |
| Dec 2024 | $2.8M |
| Sep 2024 | $2.8M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM SCND
| FY Dec 2025 | n/a |
| FY Dec 2024 | -60.2% |
| FY Dec 2023 | -81.8% |
| FY Jun 2022 | -119.9% |
| FY Jun 2021 | n/a |
| Jun 2026 | -83.9% |
| Mar 2026 | -129.5% |
| Dec 2025 | -117.6% |
| Sep 2025 | +284.5% |
| Jun 2025 | -65.4% |
| Mar 2025 | -73.9% |
| Dec 2024 | -68.6% |
| Sep 2024 | -42.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM SCND
| FY Dec 2025 | -$4.5M |
| FY Dec 2024 | -$3.8M |
| FY Dec 2023 | -$6.3M |
| FY Jun 2022 | n/a |
| FY Jun 2021 | -$3.8M |
| Jun 2026 | -$912.4K |
| Mar 2026 | -$999.7K |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -$1.7M |
| Mar 2025 | -$1.5M |
| Dec 2024 | -$401.8K |
| Sep 2024 | -$871.6K |
At each fiscal year end
Single quarter
Debt to equity
0.05x
long-term debt only, 2021-03-31 (63 months older than the period end); equity 2026-06-30
Debt to equity SCND
| FY Dec 2025 | 0.04x |
| FY Dec 2024 | 0.05x |
| FY Dec 2023 | 0.03x |
| FY Jun 2022 | 0.02x |
| FY Jun 2021 | 0.02x |
| Jun 2026 | 0.05x |
| Mar 2026 | 0.05x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.03x |
| Jun 2025 | 0.05x |
| Mar 2025 | 0.06x |
| Dec 2024 | 0.05x |
| Sep 2024 | 0.04x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt SCND
| FY Dec 2025 | -10.26x |
| FY Dec 2024 | -8.49x |
| FY Dec 2023 | -14.19x |
| FY Jun 2022 | n/a |
| FY Jun 2021 | -8.25x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -10.26x |
| Sep 2025 | -10.26x |
| Jun 2025 | -10.26x |
| Mar 2025 | -8.39x |
| Dec 2024 | -8.49x |
| Sep 2024 | -10.69x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-9.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SCND
| FY Dec 2025 | -12.3% |
| FY Dec 2024 | -56.0% |
| FY Dec 2023 | -63.4% |
| FY Jun 2022 | -62.5% |
| FY Jun 2021 | -19.4% |
| Jun 2026 | -9.3% |
| Mar 2026 | -12.2% |
| Dec 2025 | -12.3% |
| Sep 2025 | -10.6% |
| Jun 2025 | -65.4% |
| Mar 2025 | -60.6% |
| Dec 2024 | -56.0% |
| Sep 2024 | -64.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-7.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SCND
| FY Dec 2025 | -10.1% |
| FY Dec 2024 | -45.6% |
| FY Dec 2023 | -52.2% |
| FY Jun 2022 | -54.7% |
| FY Jun 2021 | -16.8% |
| Jun 2026 | -7.3% |
| Mar 2026 | -9.5% |
| Dec 2025 | -10.1% |
| Sep 2025 | -8.9% |
| Jun 2025 | -52.3% |
| Mar 2025 | -47.3% |
| Dec 2024 | -45.6% |
| Sep 2024 | -51.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SCND
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2022 | n/a |
| FY Jun 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-81.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SCND
| FY Dec 2025 | -74.9% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -60.0% |
| FY Jun 2022 | -50.7% |
| FY Jun 2021 | -23.9% |
| Jun 2026 | -81.2% |
| Mar 2026 | -82.5% |
| Dec 2025 | -74.9% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -65.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SCND
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2022 | n/a |
| FY Jun 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$8.1M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term debt only, 2021-03-31 (63 months older than the period end), minus cash 2023-09-30
Enterprise value SCND
| FY Dec 2025 | $6.6M |
| FY Dec 2024 | $9.4M |
| FY Dec 2023 | $16.7M |
| FY Jun 2022 | $33.9M |
| FY Jun 2021 | $38.6M |
| Jun 2026 | $6.8M |
| Mar 2026 | $8.7M |
| Dec 2025 | $6.6M |
| Sep 2025 | $8.0M |
| Jun 2025 | $7.4M |
| Mar 2025 | $9.9M |
| Dec 2024 | $9.4M |
| Sep 2024 | $13.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield SCND
| FY Dec 2025 | -67.6% |
| FY Dec 2024 | -40.0% |
| FY Dec 2023 | -37.6% |
| FY Jun 2022 | n/a |
| FY Jun 2021 | -7.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -67.6% |
| Sep 2025 | -55.9% |
| Jun 2025 | -60.6% |
| Mar 2025 | -37.3% |
| Dec 2024 | -40.0% |
| Sep 2024 | -35.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SCND
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jun 2022 | n/a |
| FY Jun 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.1M | $10.7M | $11.1M | n/a |
| Gross profit | $1.3M | $2.0M | $5.1M | n/a |
| Operating income | -$7.9M | -$8.2M | -$9.3M | n/a |
| Net income | -$1.2M | -$6.4M | -$9.1M | n/a |
| EPS (diluted) | -0.11 | -0.61 | -1.27 | n/a |
| Operating cash flow | n/a | -$3.7M | -$6.2M | n/a |
| Cash | n/a | n/a | n/a | $1.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
SCND Stock Sonar score 5/7 axes
Find similar shapesCompareSCND ranks highest on risk and compliance (79th percentile) and financial health (75th), and lowest on growth (37th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SCND filings, in plain words
Are Scientific Industries insiders buying or selling SCND?
In the 180 days to 2026-10-28, Scientific Industries insiders were net buyers, a net $17.1K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Scientific Industries insiders were net buyers of SCND, a net $17.1K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
